Skip to content

13F-HR filed by GREAT POINT PARTNERS LLC

GREAT POINT PARTNERS LLC filed this 13F-HR for the quarter ended 2016-09-30, filed 2016-11-14, with 35 holding rows worth $392,073,000.

Accession
0000930413-16-008703
Filed
2016-11-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2016

A holdings report, 35 entries on the cover page, a total value of $392,073,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $392,073,000 with VALUE read as thousands by filing date, 13F file number 028-11743. The quarter's positions are built on this report. The resolved quarter.

Other managers

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
VANDA PHARMACEUTICALS INC921659108COM2,706,134$45,030,000thousands by filing date
ADAMAS PHARMACEUTICALS INC00548A106COM2,601,351$42,688,000thousands by filing date
SYNERGY PHARMACEUTICALS DEL871639308COM NEW6,422,232$35,386,000thousands by filing date
ZOGENIX INC.98978L204Common Stock2,440,959$27,900,000thousands by filing date
FOAMIX PHARMACEUTICALS LTDM46135105SHS2,769,425$25,645,000thousands by filing date
DERMIRA INC24983L104COM679,403$22,977,000thousands by filing date
IGNYTA INC451731103COM3,475,227$21,859,000thousands by filing date
ENANTA PHARMACEUTICALS INC29251M106COM790,000$21,022,000thousands by filing date
NEUROCRINE BIOSCIENCES INC64125C109COM394,080$19,956,000thousands by filing date
AVEXIS INC05366U100COM381,095$15,703,000thousands by filing date
MERRIMACK PHARMACEUTICALS IN590328100COM2,442,159$15,508,000thousands by filing date
COLUCID PHARMACEUTICALS INC19716T101COM400,000$15,260,000thousands by filing date
BOVIE MEDICAL CORP10211F100COM2,680,000$13,963,000thousands by filing date
SAGE THERAPEUTICS INC78667J108COM264,893$12,198,000thousands by filing date
CONNECTURE INC COM20786J106Stock4,127,232$7,759,000thousands by filing date
ARADIGM CORP038505400COM NO PAR NEW1,002,962$6,900,000thousands by filing date
OCERA THERAPEUTICS INC COM67552A108COM1,963,777$5,184,000thousands by filing date
DBV TECHNOLOGIES S A23306J101ADR131,452$4,776,000thousands by filing date
SUNESIS PHARMACEUTICALS INC867328700COM1,063,573$4,648,000thousands by filing date
ALIMERA SCIENCES INC016259103COM2,637,969$3,931,000thousands by filing date
BIOCRYST PHARMACEUTICALS INC COM09058V103Stock725,000$3,197,000thousands by filing dateput
GW PHARMACEUTICALS PLC36197T103ADS23,800$3,159,000thousands by filing dateput
DIPEXIUM PHARMACEUTICALS INC25456J104COM178,930$2,594,000thousands by filing date
TENAX THERAPEUTICS INC88032L100COM1,108,593$2,568,000thousands by filing date
PDL BIOPHARMA INC69329Y104COM645,000$2,161,000thousands by filing date
TETRAPHASE PHARMACEUTICALS INC88165N105COMMON STOCK452,375$1,733,000thousands by filing date
CATABASIS PHARMACEUTICALS IN14875P107COM250,000$1,540,000thousands by filing date
MIRATI THERAPEUTICS INC60468T105COM227,657$1,505,000thousands by filing date
SERES THERAPEUTICS INC81750R102COM120,000$1,475,000thousands by filing date
SERES THERAPEUTICS INC81750R102COM120,000$1,475,000thousands by filing dateput
Rocket Pharmaceuticals Inc45780V102SHS94,077$892,000thousands by filing date
NOVAVAX INC670002104COMMON STOCK409,200$851,000thousands by filing datecall
STREAMLINE HEALTH SOLUTIONS86323X106COM151,611$279,000thousands by filing date
ARDELYX INC039697107COM15,000$194,000thousands by filing date
OPHTHOTECH CORP683745103COM3,400$157,000thousands by filing datecall

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0000930413-16-008703this filing2016-11-14acceptance time not in the bulk data set